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COMPLEX ATTENTION-DEFICIT/HYPERACTIVITY DISORDER: PATIENT 
CHARACTERISTICS, HEALTH CARE UTILIZATION AND COSTS IN A 
RETROSPECTIVE OBSERVATIONAL CLAIMS STUDY
Hess G1, Sasane R2, Hill J1, Hodgkins P2, Shah MR1
1SDI Health, Plymouth Meeting, PA, USA, 2Shire Pharmaceuticals, Wayne, PA, USA
OBJECTIVES: To elucidate the characteristics of complex Attention-Deﬁcit/Hyperac-
tivity Disorder (ADHD) and associated health care utilization and costs in children 
and adolescents. METHODS: Patients (aged 6–17) diagnosed with ADHD between 
November 2005 and October 2007 and with medical/pharmacy claims for q1 year 
after the index diagnosis were identiﬁed retrospectively from SDI’s databases of 
patient-level medical and pharmacy claims. Because patients with ADHD and associ-
ated comorbidities were likely to require the most treatment (and therefore incur 
higher health care charges), we hypothesized that total cost of ADHD prescriptions 
and ofﬁce visits could serve as a proxy for a more “complex” patient. Costs for ADHD 
prescriptions and ADHD ofﬁce visits were aggregated, and patients were stratiﬁed into 
high- (top 25% of total charges), medium- (middle 50%), and low- (bottom 25%) 
cost groups. RESULTS: In total, 10,362 patients were stratiﬁed, with 2591 patients 
in the high-cost, 5170 in the medium-cost, and 2601 in the low-cost group. More than 
two thirds of the patients were aged 6–12 years, and 70% were male. The prevalence 
of most psychiatric and other comorbidities was higher in the high-cost group than 
in the medium-cost group (P  0.05 for 10 of 14 comorbidities) or in the low-cost 
group (P  0.05 for 9 comorbidities). High-cost patients were also more likely to be 
diagnosed younger, be treated by a specialist, and use augmented pharmacotherapy 
for their ADHD. Health care resource utilization in the high-cost group was 1.77 times 
greater than in the medium-cost group and 3.52 times greater than in the low-cost 
group (P  0.001 for both comparisons). The proportion of ADHD physician visits 
with procedure codes indicating higher disease burden and complexity was also sig-
niﬁcantly greater (P  0.001) for the high-cost group. CONCLUSIONS: This study 
identiﬁed a subset of complex pediatric and adolescent ADHD patients with unique 
characteristics and higher relative resource use. Supported by funding from Shire 
Development Inc.
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DEPRESSION TREATMENT ADHERENCE AMONG DEPRESSION 
PATIENTS WITH COMORBIDITY
Rhee Y, Jordan N, Ziffra M, Mohr D
Northwestern University, Chicago, IL, USA
OBJECTIVES: To examine the impact of comorbidity on treatment options and treat-
ment adherence among depression patients in employer health plans. METHODS: We 
used 165,569 records of administrative claims data between September 2002 and 
March 2004 for employed between 18 to 64 years old. Depression was identiﬁed using 
ICD-9 diagnosis codes. Treatment adherence was deﬁned as ﬁnding more than 2 pre-
scriptions for antidepressants (30 days supply) or having more than 5 psychotherapy 
sessions. Multivariate logistic regression analyses were performed to examine impact 
of comorbidity on adherence to treatment among depression patients who initiated 
treatment. RESULTS: Among eligible members, 2567(1.5%) had a primary diagnosis 
of depression and received treatment. Over 70% were female and the average age was 
42.6 years. Approximately half (49.2%) received medication only; 29.3 % received 
psychotherapy and medication; and 15.7% received psychotherapy without medica-
tions. The average number of prescribed antidepressants was 4.4 among those took 
any medications. Among those who had psychotherapy, 51.4% received more than 5 
secessions. The most frequent comorbid mental disorders were anxiety (25.3%), 
adjustment disorder (9.1%), alcohol use (3.5%) and substance abuse (1.9%) and 
physical comorbid conditions were musculoskeletal and chronic pain (MSCP, 29.9%), 
injuries (17.5%), hypertension (13.3%), asthma (6.7%), diabetes (6.4%), arthritis 
(5.1%), and urinary tract infection (4.0%). Depression patients with anxiety (OR  
1.9), or adjustment disorder (OR  1.4) were signiﬁcantly more likely to receive psy-
chotherapy (p  0.05), but signiﬁcantly less likely to use medication only. Comorbid 
HIV (OR  1.7), arthritis (OR  0.5), anxiety (OR  0.4) and MSCP (OR  0.3) were 
signiﬁcantly associated with receiving both medication and psychotherapy (p  0.001). 
Among patients who received both treatments, those with hypertension were signiﬁ-
cantly less likely to adhere to either treatment. Among those who initiated psycho-
therapy, comorbid anxiety (OR  0.6) was signiﬁcantly associated with treatment 
adherence (p  0.001). CONCLUSIONS: Among depression patients, having 
comorbid mental disorders was signiﬁcantly associated with use of and adherence 
to psychotherapy treatment.
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A PATIENT PERSPECTIVE ON SIDE EFFECTS OF ANTIPSYCHOTIC 
THERAPY: THE TOOL INSTRUMENT
Lindström E1, Jönsson L2, Berntsson A3
1Malmö University Hospital, Malmö, Sweden, 2i3 Innovus, Stockholm, Sweden, 3Danderyds 
hospital, STOCKHOLM, Sweden
OBJECTIVES: Pharmacotherapy is the most important component of care for patients 
with schizophrenia and related disorders. However, side effects adversely affect 
patient’s health-related quality of life. A novel self-assessment instrument (Tolerability 
and quality of Life, TooL) is presented to assess patient experiences of side effects. 
METHODS: The instrument was developed to reﬂect the subjective perception of side 
effects in patients treated with antipsychotic medication. TooL was developed by an 
expert panel of four experienced psychiatrists with a special interest in the treatment 
of schizophrenia, schizoaffective or bipolar syndrome. TooL has eight domains reﬂect-
ing important aspects for patient well-being: anxiety and depression, usual activities, 
fatigue or weakness, body weight, stiffness and tremor, bodily restlessness, sexual 
function and vertigo or nausea. TooL was completed by 220 patients with schizophre-
nia, bipolar disorder or schizoaffective disorder in a cross-sectional observational 
study. Reliability and validity were estimated by correlations with existing scales 
assessing presence of side effects, symptom severity and HRQoL (UKU, PANSS, 
MADRS, SWN, EQ-5D, and VAS). RESULTS: Responses on TooL demonstrated 
that frequent experiences of side-effects impact the well-being of patients. Validity 
was supported by signiﬁcant correlations with other instruments. TooL correlated 
with corresponding domains in the UKU scale. The MADRS score correlated strongest 
with anxiety, depression, fatigue or weakness. The global PANSS score signiﬁcantly 
correlated with all domains except Weight gain, Stiffness and Sexual function. TooL 
also correlated to the VAS score, EQ-5D, and the disease-speciﬁc scale SWN. 
 CONCLUSIONS: TooL is a new instrument for patient-reported assessment of the 
impact of side-effects of antipsychotic medication. The instrument can be of signiﬁcant 
value in a clinical setting as a decision tool to guide treatment choices and serve as an 
important input to evaluations of antipsychotic treatment. Patient experiences of side 
effects are a highly relevant outcome measure that may determine the long-term 
success of therapy.
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NON-ADHERENCE TO ORAL ANTIPSYCHOTICS IN SCHIZOPHRENIA: 
RELAPSE AND UTILIZATION OF HEALTH CARE RESOURCES IN A  
6-MONTH FOLLOW-UP PERIOD
San L1, Valladares A2, Bernardo M3, Olivares JM4, Ciudad A2, García-Polavieja P2, 
Yruretagoyena B2, Dilla T2, Gilaberte I2
1Hospital Sant Joan de Déu, Esplugues de Llobregat, Barcelona, Spain, 2Lilly, S.A., Alcobendas, 
Madrid, Spain, 3Hospital Clinic, Barcelona, Barcelona, Spain, 4Hospital Meixoeiro—Complejo 
Hospitalario Universitario de Vigo, Vigo, Pontevedra, Spain
OBJECTIVES: To investigate the clinical proﬁles, modiﬁcation of therapeutic strate-
gies, relapse rate and resource utilization in patients with schizophrenia who are 
at risk of non-adherence to oral antipsychotic (AP) medication. METHODS: A 
Spanish cohort of 596 outpatients with schizophrenia whose therapy was modiﬁed 
because of risk of non-adherence to oral AP medication was followed during 12 
months. Baseline and 6-month data on sociodemographic and clinical characteristics, 
as well as on resource utilization are described. RESULTS: Patients’ mean (SD) age 
was 40.1 (11.1) years, and 64% were males. The median (IQR) time-since-diagnosis 
was 14 (15) years. Within the prior 6 months, 124 (21%) had been hospitalized at 
least once with mean duration of 26 days. Patients had severe symptoms (CGI-S mean 
score of 4.3), poor quality of life (mean EuroQol-5D health-status value of 0.6) 
and functional status (mean SOFAS score of 50.6). Baseline non-pharmacologic thera-
pies were modiﬁed in 189 (32%) patients, AP medication in 503 (85%) and concomi-
tant medication in 15%. Modiﬁcations of AP medications were mostly dose 
adjustments (64%). Depot formulation was started by 15%. After 6 months, 65 
patients (11%) relapsed. These had worse CGI-S and SOFAS scores than patients who 
did not relapse (4.2 and 51.4 versus 3.7 and 58.6, respectively), whilst EuroQol-5D 
scores were similar (0.7 in both groups). Hospitalization was required by 35 out of 
65 (53.9%) patients who relapsed (38.7 days on average), but just by 5 out of 531 
(0.9%) of those who did not relapse (5.4 days on average). Visits to emergency room 
occurred, respectively, in 44 out of 65 (67.7%) and in 74 out of 531 patients (14%). 
CONCLUSIONS: After baseline treatment modiﬁcation the proportion of patients 
requiring hospitalizations within 6 months was reduced. Patients who relapsed con-
sumed more resources.
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TOOL: MULTI-ATTRIBUTE UTILITY FUNCTION REFLECTING PATIENT 
EXPERIENCE OF SIDE EFFECTS TO ANTIPSYCHOTIC THERAPY
Jönsson L1, Lang A2, Lindström E3
1i3 Innovus, Stockholm, Sweden, 2i3 Innovus, 11164, Sweden, 3Malmö University Hospital, 
Malmö, Sweden
OBJECTIVES: The main effects of pharmaceutical treatment in schizophrenia are 
symptom relief and relapse prevention. Antipsychotic treatment is, however, associ-
ated with adverse effects that impact patient well-being. A novel instrument, TooL 
(Tolerability and quality of Life), measures health-related quality of life with antipsy-
chotic medication across eight different dimensions: mood, function capabilities, 
fatigue, weight gain, stiffness and tremor, physical restlessness, sexual dysfunction and 
nausea. This study aimed to develop a function linking responses to TooL to health 
utility values. METHODS: A multi-attribute utility function (MAUF) was developed 
based on the instrument for patients with schizophrenia, schizoaffective or bipolar 
syndrome on antipsychotic treatment to allow estimation of health utilities associated 
with antipsychotic treatments and their side effects. 220 patients with stable schizo-
phrenia, schizoaffective disorder or bipolar disorder completed a set of ratings to 
facilitate the estimation of a MAUF linking each possible state in the classiﬁcation 
system to a utility value. RESULTS: A total of 183 of the 220 patients provided 
complete and consistent ratings allowing an average utility function to be estimated. 
The TooL utility ratings correlated signiﬁcantly with disease speciﬁc instruments for 
disease severity (MADRS and PANSS) and quality of well-being (SWN). Utility ratings 
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were, furthermore, more sensitive to the presence of side effects than EQ-5D. 
 CONCLUSIONS: TooL is a novel system for measuring health utilities in patients 
with schizophrenia, schizoaffective disorder or bipolar depression that incorporates 
the patient perspective of side effects of antipsychotic treatment. Adverse effects from 
antipsychotic treatment impact the quality-of-life and should be taken into account in 
economic evaluations of treatments with different side effect proﬁles. TooL facilitates 
cost-utility analyses that reﬂect this important aspect of treatment choice and 
outcome.
PMH59
FURTHER VALIDITY EVIDENCES OF THE GENERALIZED ANXIETY 
DISORDER—7 SCALE (GAD-7)
Ruiz MA1, Zamorano E2, García-Campayo J3, Pardo A1, Freire O4, Rejas J4
1Universidad Autónoma de Madrid, Madrid, Spain, 2Sant Antoni de Vilamajor Primary Care 
Center, ABS Alt Mogent, Barcelona, Spain, 3Hospital Miguel Servet, Zaragoza, Spain, 4Pﬁzer 
Spain, Madrid, Spain
OBJECTIVES: To investigate the relationship of severity levels of anxiety identiﬁed 
by the GAD-7 scale and the degree of disability as assessed by other standard widely 
used questionnaires. METHODS: A random sample of 212 subjects was recruited in 
Mental Health and Primary Care centres; 50% diagnosed of Generalized Anxiety Dis-
order (GAD) by DSM-IV criteria, and the other 50% were concurrent matched con-
trols. In addition to the GAD-7, the following scales were also administered: Hamilton 
Anxiety scale (HAM-A), Hospital Anxiety and Depression Scale (HADS), and World 
Health Organization Disability Scale (WHO-DAS). The number of visits to primary 
care and specialized services were also measured. Correlations between scale scores 
were computed and also agreement between instrument-speciﬁc disability and severity 
levels. RESULTS: Strong and signiﬁcant (p  0.001) correlations were found between 
GAD-7 scores and other questionnaires: HAM-A (r  0.852), HADS-A (r  0.903), 
WHO-DAS (r  0.704). Although GAD-7 scores correlated with all WHO-DAS dimen-
sions, higher correlations were observed with Social Participation (r  0.741), Com-
prehension and Communication (r  0.679), and Labour (0.638) dimensions. Moderate 
but signiﬁcant correlations were also found between GAD-7 scores and the number 
of visits to Primary Care (r  0.393) and Specialized Services (r  0.373). HAM-A 
severity groups presented signiﬁcant differences in GAD-7 mean scores (F  205.3; 
df1  3; df2  208; p  0.001), and HAM severity groups also differed (F  175.3; 
df1  3; df2  208; p  0.001); in both cases all severity levels differed. CONCLU-
SIONS: The GAD-7 scale has shown to highly correlate not only with speciﬁc anxiety 
measures but also with disability measures. Not all WHO-DAS disability dimensions 
seem to be equally affected by GAD levels, and it has been shown that more 
severe GAD levels tend to demand more health attention. As the GAD-7 is self-admin-
istered and it is no time consuming, this instrument could be a good choice in primary 
care settings to explore the level of patient’s disability in subjects with GAD.
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A CONCEPTUAL MODEL OF ‘CLEAR THINKING’ RELEVANT TO 
PATIENTS DIAGNOSED WITH SCHIZOPHRENIA
Bridges JF1, dosReis SC2, Margolis RL2, Everett AS3
1Johns Hopkins University, Bloomberg School of Public Health, Baltimore, MD, USA, 2Johns 
Hopkins University, School of Medicine, Baltimore, MD, USA, 3Johns Hopkins Bayview 
Medical Center, Baltimore, MD, USA
BACKGROUND: IQWiG, the German health technology assessment agency, is 
required to focus on patient-relevant endpoints as part of their cost-beneﬁt analysis. 
Several patient preference studies conducted in Germany have identiﬁed “clear think-
ing” as a patient-relevant endpoint, but the measurement of this construct is limited 
by the absence of a conceptualization of clear thinking that is grounded in the patient 
experience. OBJECTIVES: To develop a conceptual model of clear thinking grounded 
in the experience of patients diagnosed with schizophrenia, aiding the creation of clear 
thinking scale. METHODS: A trained psychologist elicited deﬁnitions and examples 
of clear thinking from 25 German patients diagnosed with schizophrenia during open-
end, semi-structured interviews. Theory building was aided by literature review, 
including a review of existing scales of cognition, and an additional 15 depth inter-
views with patients and clinicians. Data was analyzed using a grounded theory 
approach, leading to multi-dimensional conceptualization of clear thinking. RESULTS: 
Clear thinking can be conceptualized by four themes: a) staying organized (including 
daily activities, making decisions and having organized thoughts); b) making sense of 
the world (identifying reality, verbal comprehension and visual comprehension); c) 
feeling clear headed (confusion, slowness and pacing); and d) expressing thoughts and 
feelings (feelings, communication and fullness of life). CONCLUSIONS: This concep-
tual model provides researchers and clinicians with a framework to consider clear 
thinking as deﬁned by patients diagnosed with schizophrenia. It will also provide the 
cornerstone for the development of a clear thinking scale to measure this patient-
 relevant endpoint and subsequently assess the validity of our conceptualization.
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PATIENTS PREFERENCES IN ADULTS WITH ADHD—A DISCRETE 
CHOICE EXPERIMENT
Mühlbacher AC1, Slawik L2, Kasper J3, Nübling M4
1Hochschule Neubrandenburg, Neubrandenburg, Germany, 2Janssen Cilag GmbH, Neuss, 
Germany, 3GEB: Gesellschaft für Empirische Beratung mbH—Empirical Consulting -, Freiburg, 
Germany, 4Gesellschaft für empirische Beratung mbH, D- 79211 Denzlingen, Germany
OBJECTIVES: For the majority of those concerned, ADHD is a lifelong chronic 
disease with prevalent underachievement in work life and impairments in social 
functioning. While clinical evidence on efﬁcacy and tolerability of treatment options 
for ADHD in adulthood is increasing, preferences of adults with ADHD have not yet 
been explored. Understanding their preferences contributes to present discussions in 
the health care sector on patients’ needs and shared decision-making. METHODS: An 
extended qualitative study (literature review, in-depth interviews and patient focus 
groups) was conducted in order to collect all relevant factors and success criteria for 
adults with ADHD (content validity). In the subsequent quantitative study, preferences 
for an ADHD treatment were investigated by using direct measurement (rating 23 
aspects on a ﬁve point Likert-scale) as well as a Discrete-Choice-Experiment (DCE) 
with 8 pairs of treatment options described by 6 dichotomous parameters. RESULTS: 
14 in-depth interviews and ﬁve focus groups with 4–12 adult participants each (n  
35) were conducted. 329 persons (18- 65 years, 63%female) ﬁlled the questionnaire 
of the quantitative study (89% online, 11% paper&pencil). In the direct assessment, 
“long-term positive effects (e.g. behaviour changes)”, “improved ability to concen-
trate”, “allows “normal” daily living” and “improves emotional stability” reached 
the highest values (means around 90). In the DCE (random effects logit model) “social 
abilities (profession, friendship possible)” had the highest impact on choices (coefﬁ-
cient 2.12) followed by “long-term behaviour changes” (1.75), “fast symptom relief” 
(1.10), “no impact on positive ADHD traits” (1.04), and “emotional stability (no 
mood swings)” (0.81). These factors were highly signiﬁcant (p  0.001) while “neces-
sity of medical treatment” had no signiﬁcant inﬂuence. CONCLUSIONS: The pre-
sented study systematically explored patient preferences and hereby contributes to a 
better understanding of the medical needs of adults diagnosed with ADHD. The 
achievement of social abilities and long lasting behavioural effects attributed greatest 
beneﬁt to the respondents.
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THE SPANISH VERSION OF THE TOOL QUESTIONNAIRE: VALIDATION 
OF A SPECIFIC MEASURE TO EVALUATE HEALTH RELATED QUALITY 
OF LIFE (HRQOL) IN PATIENTS WITH SCHIZOPHRENIA AND BIPOLAR 
DISORDER
Maurino J1, Cordero L2, Montejo AL3, Correas Lauffer J4, Cuervo J5, Rebollo P5, Diez T2, 
Hernandez R2
1AstraZeneca, Madrid, Spain, 2AstraZeneca Farmacéutica Spain S.A, Madrid, Spain, 3Hospital 
Universitario de Salamanca, Salamanca, Spain, 4Hospital del Henares, Coslada, Spain, 5BAP 
Health Outcomes Research, Oviedo, Spain
OBJECTIVES: To develop a cross-cultural adaptation from Swedish into Spanish of 
the TooL questionnaire—a previously validated instrument to assess side effects’ 
impact on HRQoL in patients with schizophrenia and bipolar disorder. METHODS: 
An epidemiological multicentre, cross-sectional study was carried out to analyze the 
psychometric properties of the Spanish TooL. It comprises 8 attributes and 4 levels 
per domain (Likert scale: 1-minimun impact; 4-maximun impact): worry-upset, func-
tion capabilities, fatigue-weakness, weight gain, stiffness-tremor, physical restlessness, 
sexual dysfunction, and dizziness-nausea. Patients completed both generic and speciﬁc 
measures of HRQoL and severity (EQ-5D and SF6D –unweighted- and the Clinical 
Global Impression -CGI-SI-, UKU side effects rating scale, Positive and Negative Syn-
drome scale, Young Mania Rating Scale, Montgomery Adsberg Depression Rating 
Scale). Reliability (Cronbach’s A and intraclass correlation coefﬁcient –ICC-), con-
struct validity (factorial analysis –FA- and item-total correlations -ITC), convergent 
validity (Spearman’s rank correlations between measures –rs-) and criterion validity 
(Mann-Whitney U differences between mild vs moderate-severe patients according to 
CGI-SI) were evaluated. RESULTS: A total of 242 patients were included (121 with 
schizophrenia and 121 with bipolar disorder). Internal consistency and ICC were 
adequate (Cronbach’s A  0.757 & ICC  0.90). FA and ITC showed that one-
 dimensional structure could be assumed (1 eigenvalue 1 and 40% of variance 
explained). Correlations (rs) between the Spanish TooL and both generic and speciﬁc 
measures were moderate-high. Differences in the Spanish TooL scores between mild 
vs moderate-severe patients were highlighted. CONCLUSIONS: The Swedish TooL 
questionaire was culturally adapted and validated into Spanish. Further investigation 
is needed to test the sensitivity of the Spanish TooL questionnaire.
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ESTIMATION OF A MULTI-ATTRIBUTE UTILITY FUNCTION FOR THE 
SPANISH VERSION OF THE TOOL QUESTIONNAIRE
Cordero L1, Montejo AL2, Correas Lauffer J3, Villa G4, Rebollo P5, Maurino J1, Diez T1, 
Hernandez R1
1AstraZeneca Farmacéutica Spain S.A, Madrid, Spain, 2Hospital Universitario de Salamanca, 
Salamanca, Spain, 3Hospital del Henares, Coslada, Spain, 4BAP Health Outcomes, Oviedo, 
Asturias, Spain, 5BAP Health Outcomes Research, Oviedo, Spain
OBJECTIVES: To estimate and assess the psychometric properties of a Multi-Attribute 
Utility Function for the Spanish version of the TOOL questionnaire (TOOL MAUF). 
TOOL is a recently developed 8-item (4-level) instrument measuring antipsychotics 
side effects´ impact on health status. METHODS: Balanced data on 242 patients 
diagnosed with schizophrenic or bipolar disorders were gathered. In addition to 
demographic and clinical variables, and the usual generic HRQoL questionnaires, 
EQ5D and SF6D, instruments considered included the Spanish versions of the Positive 
and Negative Syndrome Scale (PANSS), Young Mania Rating Scale (YMRS), Mont-
gomery-Asberg Depression Rating Scale (MADRS), UKU side effect rating scale, and 
TOOL questionnaire. TOOL MAUF parameters estimation involved a number of VAS 
and TTO ratings of different health states deﬁned from TOOL items. Such ratings 
proved hard to be performed by patients. After checking for inconsistencies in patient 
responses (missing data, out-of-range responses, and rating reversals), the original 
